Therapy News and Research

RSS

Promising results for dabrafenib in advanced melanoma

The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

8 Jun 2012

Genetic influence on postmenopausal bone loss falls with age

The effect of genetics on bone loss rates in postmenopausal women reduces until the age of 65 years, after which time its influence disappears completely, according to results from a twin-based study.

8 Jun 2012

Rheumatoid arthritis drug has added benefits

Treatment with anti-tumor necrosis factor drugs reduces the risk for cardiovascular events in patients with rheumatoid arthritis, researchers report.

8 Jun 2012

CSL Behring rIX-FP granted Orphan Drug Designation to treat hemophilia B

CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).

8 Jun 2012

NCPA takes proactive steps against medication non-adherence

Under the leadership of its national trade association, community pharmacists are stepping up to the plate to take on the issue of medication non-adherence, a health care crisis currently adding to the nation's fiscal woes at a cost of nearly $300 billion each year.

8 Jun 2012

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Amgen today announced top-line results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis.

8 Jun 2012

Smoking RA patients don't respond to anti-TNF drugs

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs.

8 Jun 2012

Research roundup: Savings from electronic health records?

Does Health Information Exchange Reduce Unnecessary Neuroimaging and Improve Quality of Headache Care in the Emergency Department?

8 Jun 2012

NKI-AVL, Elekta partner to advance cancer research

Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital have signed a strategic alliance to advance cancer research.

From Elekta 8 Jun 2012

eHealth offers Europe solutions that can help avoid healthcare crisis

Healthcare systems face enormous challenges over the coming years. The increasing demands of an aging population, the rising cost of treatments and medications, and budget shortfalls are all issues that will need to be addressed if Europeans are to continue to enjoy high standards of care. eHealth, enabled by information and communication technologies, offers Europe solutions that can help avoid healthcare crisis.

8 Jun 2012

Accuray announces outcome data from CyberKnife Prostate SBRT study

Accuray Incorporated, the premier radiation oncology company, announced today that outcome data on intermediate risk prostate cancer patients treated with CyberKnife Prostate SBRT was presented at the American Urological Association Meeting (AUA) 2012 held in Atlanta, Ga.

8 Jun 2012

Decision Resources forecasts the launch of four new agents to treat DMD by 2021

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that interviewed experts unanimously identify a disease-modifying therapy as the highest unmet need in the treatment of Duchenne muscular dystrophy (DMD).

8 Jun 2012

Erivedge drug shows promise against advanced basal cell carcinoma

It's the most common form of skin cancer, but in its advanced stages, basal cell carcinoma has the potential to become disfiguring and life threatening. An international phase 2 study headed by Mayo Clinic led to the recent Food and Drug Administration approval of the first drug of its kind to help advanced basal cell carcinoma patients who have few treatment options.

8 Jun 2012

Study: HIV superinfection may be more common than previously believed

Human immunodeficiency virus (HIV) superinfection may be as common as initial HIV infection and is not limited to high risk-populations, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and the National Institute of Allergy and Infectious Diseases.

8 Jun 2012

Experts debate whether spinal manipulation for neck pain should be abandoned

The effectiveness of spinal manipulation divides medical opinion. On bmj.com today, experts debate whether spinal manipulation for neck pain should be abandoned.

8 Jun 2012

Tp53 genetic mutation may play an important role in prostate cancer

A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.

8 Jun 2012

HIV superinfection may be more frequent among general population of Uganda

HIV superinfection, when a person with HIV could acquire a second, new strain of HIV, may occur as often as initial HIV infection in the general population in Uganda, a study suggests.

8 Jun 2012

Modulation Therapeutics receives MMRF grant for new multiple myeloma treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $500,000 through its Biotech Investment Award (BIA) program to Modulation Therapeutics. Since the inception of this MMRF program in 2006, $11.5 million has been committed to 12 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

8 Jun 2012

Scientists discover new function for thrombospondin protein

Scientists have discovered a new function for a protein that protects cells during injury and could eventually translate into treatment for conditions ranging from cardiovascular disease to Alzheimer's.

8 Jun 2012

Women may need stronger lipid-lowering regimens

Women who are at high risk for cardiovascular disease are significantly less likely to achieve their lipid-lowering treatment goals than their male counterparts, show findings from a Chinese study.

7 Jun 2012